- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting B-cell maturation antigen in multiple myeloma
Authors
Keywords
-
Journal
Immunotherapy
Volume 7, Issue 11, Pages 1187-1199
Publisher
Future Medicine Ltd
Online
2015-09-15
DOI
10.2217/imt.15.77
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
- (2015) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Blinatumomab: First Global Approval
- (2015) Mark Sanford DRUGS
- Blinatumomab for the treatment of B-cell lymphoma
- (2015) Eunhye Oak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma
- (2015) Nitya S. Ramadoss et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Adoptive cellular therapy: A race to the finish line
- (2015) Carl H. June et al. Science Translational Medicine
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Robust isolation of malignant plasma cells in multiple myeloma
- (2014) I. Frigyesi et al. BLOOD
- CARTs on the Road for Myeloma
- (2014) M. V. Maus et al. CLINICAL CANCER RESEARCH
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Daratumumab granted breakthrough drug status
- (2014) Jacob P Laubach et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma
- (2014) Jesus Berdeja Frontiers in Bioscience-Landmark
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
- (2014) Saar Gill et al. IMMUNOLOGICAL REVIEWS
- Current treatment landscape for relapsed and/or refractory multiple myeloma
- (2014) Meletios A. Dimopoulos et al. Nature Reviews Clinical Oncology
- Current strategies for treatment of relapsed/refractory multiple myeloma
- (2014) Jacob P Laubach et al. Expert Review of Hematology
- Zoom Zoom: Racing CARs for Multiple Myeloma
- (2013) M. V. Maus et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
- (2013) Hua Jiang et al. Molecular Oncology
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function
- (2012) Y.-T. Tai et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Molecular pathogenesis of multiple myeloma and its premalignant precursor
- (2012) W. Michael Kuehl et al. JOURNAL OF CLINICAL INVESTIGATION
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
- (2011) D. M. Benson et al. BLOOD
- Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
- (2011) Noopur Raje et al. CLINICAL CANCER RESEARCH
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
- (2011) S J Coles et al. LEUKEMIA
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- The immortality of humoral immunity
- (2010) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Antibody-maytansinoid conjugates for the treatment of myeloma
- (2010) Robert J. Lutz et al. mAbs
- Risky business in myeloma
- (2009) S. Lonial BLOOD
- Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
- (2009) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
- (2009) Dharminder Chauhan et al. CANCER CELL
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dellAdulto) Multiple Myeloma Working Party Perspective
- (2009) Pellegrino Musto et al. CURRENT DRUG TARGETS
- APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
- (2009) Jérôme Moreaux et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- First-line bortezomib benefits patients with multiple myeloma
- (2009) Meletios A. Dimopoulos et al. Nature Reviews Clinical Oncology
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now